Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026

Dyne Therapeutics, Inc.

Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.
Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.
Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.
Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.
Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.